The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...